biomea fusion
Franco joined Biomea Fusion as Chief Financial Officer in July 2021. He brings over 16 years of progressive experience in Biotech and Pharmaceutical industry, with public and private experience. Prior to joining us, Franco was with Graphite Bio as the Senior Vice President, Finance. Previously, he held finance and leadership positions at various biotechnology companies, including Eidos Therapeutics, Inc. where he served as Senior Vice President, Finance, Iovance Biotherapeutics, Inc., as Controller, and Pharmacyclics, Inc. as Senior Director of Accounting. Franco began his career at PricewaterhouseCoopers, where he worked in the Life Science and Venture Capital Group. He received a B.S. in Corporate Finance from San Jose State University and is a Certified Public Accountant.
This person is not in any offices
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.